Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Convatec Group Plc | CTEC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 233.00 | 11:27:12 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 233.20 | 231.80 | 235.40 | 233.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 29/7/2019 11:58 by ny boy Gap to fill on the breakout to 188/190p areaConvaTec Group Plc shows strong development within a rising trend channel in the medium long term. Rising trends indicate that the company experiences positive development and that buy interest among investors is increasing. The price has had a strong fall after the negative signal from rectangle formation at the break down through the support at 188. The objective at 152 is now met, but the formation signals further development in the same direction. The stock has broken up through the resistance at pence 147. This predicts a further rise. In case of negative reactions, there will now be support at pence 147. The stock is overall assessed as technically positive for the medium long term. Recommendation one to six months: Positive |
Posted at 02/4/2019 07:39 by robow from Citywire 26 Mar 19AJ Bell: Convatec in need of a shake-up A management shake-up at medical equipment maker Convatec (CTEC) could be the start of a new way of thinking that could benefit investors, says AJ Bell. Convatec has poached Genus’ boss Karim Bitar to be its new chief executive to lead its turnaround effort just as the former is also losing its chairman and deputy chairman. ‘Convatec desperately needs a new lease of life as it has been a serial disappointment for most of its time as a listed business,’ said analyst Russ Mould. Last month, the group announced plans to invest $150 million over three years and Mould said ‘the scale of such investment was significantly greater than expected, despite having scope to deliver $120 million in annual savings by 2023, as well as improvements in revenue growth and profit margins’. |
Posted at 15/10/2018 23:32 by philanderer Lex Column:'ConvaTec: scar issue' Medical products group needs more time to heal itself after investors were bloodied |
Posted at 15/10/2018 19:46 by cantrememberthis2 Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities."We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said. "With the performance wanting we would hope all options are now on the table to maximise shareholder value." |
Posted at 24/7/2018 13:32 by hazl Ah, there was a problem described by the FT in February this year,that they thought would affect first half but improve by second half of the year.Hurricanes in the DOMINICAN REPUBLIC...where they make some of their products,held them back. I think it looks like this is not only in recovery but attracting interest,not only in it's products,but as robow points out,investors....wor IMO |
Posted at 24/7/2018 13:19 by hazl Perhaps there will be more reports out now on them after this good news.I found this one from back in February where they thought they were a good buy then by the looks of it. 'Buy Convatec for recovery, says Share Centre Strong full-year results from medical technology company Convatec (CTEC) boosted the shares but they are still a ‘long way’ from their highs and remain a buying opportunity, believes The Share Centre. Analyst Helal Miah retained his ‘buy’ recommendation for ‘investors seeking a recovery potential and willing to accept a higher level of risk’ following last week’s results saw the shares rally 7%. They dipped 1%, or 2.3p, to 213p on Monday. ‘Overall the group has shown some positive progress, it operates in a defensive market with significant growth opportunities,’ ‘While the shares are a long way off from its highs, we believe this is a growth opportunity to pick up these shares for the long term.’ He added that the underlying market for Convatec is ‘defensive in nature, but growth opportunities exist from ageing populations, the increased prevalence of chronic conditions, and the fact that patients are living longer with these conditions’ |
Posted at 20/2/2018 08:12 by robow Buy Convetec for recovery,says Share CentreStrong full-year results from medical technology company Convatec (CTEC) boosted the shares but they are still a ‘long way’ from their highs and remain a buying opportunity, believes The Share Centre. Analyst Helal Miah retained his ‘buy’ recommendation for ‘investors seeking a recovery potential and willing to accept a higher level of risk’ following last week’s results saw the shares rally 7%. They dipped 1%, or 2.3p, to 213p on Monday. ‘Overall the group has shown some positive progress, it operates in a defensive market with significant growth opportunities,’ ‘While the shares are a long way off from its highs, we believe this is a growth opportunity to pick up these shares for the long term.’ He added that the underlying market for Convatec is ‘defensive in nature, but growth opportunities exist from ageing populations, the increased prevalence of chronic conditions, and the fact that patients are living longer with these conditions’. |
Posted at 16/10/2017 14:02 by pugugly Private investors stuffed yet again - Take care when Private Equity houses sell down - They normally know what they are doing and have seen rough water in the near or middle future (imo) |
Posted at 15/9/2017 16:18 by gswredland So what are the main worries for investors guys? |
Posted at 09/8/2017 14:55 by modform It's a shame that the company has so much debt that it needs 35% of its profit to service the interest. The company has a moat so will hopefully reward the patient investors |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
